In recent years, psychotropic drugs have been widely prescribed in the treatment of neuropsychiatric diseases, contributing to various changes in the periphery and central nervous system (CNS). The regulation of psychotropic drugs is like a double-edged sword, not only manifested as therapeutic efficacy but also accompanied by adverse effects. In the CNS, advances in neuroimaging may provide mechanistic insights into the neural basis of psychopathology and enable us to understand the regulatory mechanisms of psychotropic drugs from the perspective of brain structure and function.
Additionally, multiple factors have been proposed to account for the other biological changes in periphery and CNS induced by psychotropic drugs possibly through following mechanisms:1) regulation of inflammation and oxidative stress signaling; 2) accumulation of advanced glycation end products (AGEs) occurred in carbonyl stress; 3) neurotransmission signaling and treatment response; 4) brain energy metabolism (e.g. mitochondrial function); 5) a combination of environmental factors (e.g. stress).
In this Research Topic, we welcome leading experts in the field to submit their studies on animal models or human subjects, and review articles that focus on the potential mechanisms underlying the changes induced by psychotropic drugs in the treatment of neuropsychiatric disorders from the perspective of brain structure and various biological processes, thus to provide available intervention strategies, or potential therapeutic target-oriented treatment possibilities that give further insights in the treatment of neuropsychiatric disorders.
We specifically encourage submissions addressing the following subtopics:
• Brain structure and function changes induced by psychotropic drugs;
• The regulation of HPA axis and central neurotransmission-related signaling (e.g. hypersensitivity of dopamine receptor, treatment resistance);
• Inflammation and oxidative stress-related signaling pathway;
• Accumulation of advanced glycation end products (AGEs) occurred in carbonyl stress;
• Brain energy metabolism and mitochondrial dysfunction;
• Interaction between psychotropic drugs and environmental factors (e.g. stress, diet, gut microbe and etc.);
• The pathophysiological basis of relationship between metabolic disturbances and cognitive impairment
• Treatment biomarkers related to therapeutic and side effects
In recent years, psychotropic drugs have been widely prescribed in the treatment of neuropsychiatric diseases, contributing to various changes in the periphery and central nervous system (CNS). The regulation of psychotropic drugs is like a double-edged sword, not only manifested as therapeutic efficacy but also accompanied by adverse effects. In the CNS, advances in neuroimaging may provide mechanistic insights into the neural basis of psychopathology and enable us to understand the regulatory mechanisms of psychotropic drugs from the perspective of brain structure and function.
Additionally, multiple factors have been proposed to account for the other biological changes in periphery and CNS induced by psychotropic drugs possibly through following mechanisms:1) regulation of inflammation and oxidative stress signaling; 2) accumulation of advanced glycation end products (AGEs) occurred in carbonyl stress; 3) neurotransmission signaling and treatment response; 4) brain energy metabolism (e.g. mitochondrial function); 5) a combination of environmental factors (e.g. stress).
In this Research Topic, we welcome leading experts in the field to submit their studies on animal models or human subjects, and review articles that focus on the potential mechanisms underlying the changes induced by psychotropic drugs in the treatment of neuropsychiatric disorders from the perspective of brain structure and various biological processes, thus to provide available intervention strategies, or potential therapeutic target-oriented treatment possibilities that give further insights in the treatment of neuropsychiatric disorders.
We specifically encourage submissions addressing the following subtopics:
• Brain structure and function changes induced by psychotropic drugs;
• The regulation of HPA axis and central neurotransmission-related signaling (e.g. hypersensitivity of dopamine receptor, treatment resistance);
• Inflammation and oxidative stress-related signaling pathway;
• Accumulation of advanced glycation end products (AGEs) occurred in carbonyl stress;
• Brain energy metabolism and mitochondrial dysfunction;
• Interaction between psychotropic drugs and environmental factors (e.g. stress, diet, gut microbe and etc.);
• The pathophysiological basis of relationship between metabolic disturbances and cognitive impairment
• Treatment biomarkers related to therapeutic and side effects